Cargando…

Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma

SIMPLE SUMMARY: Decrease of skeletal muscle mass index during atezolizumab plus bevacizumab therapy was significantly associated with poor progression-free survival in patients with unresectable hepatocellular carcinoma, while pretreatment sarcopenia was not a significant factor. These findings sugg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumoto, Hiroaki, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Hayakawa, Yuka, Yasui, Yutaka, Uchihara, Naoki, Suzuki, Keito, Tanaka, Yuki, Miyamoto, Haruka, Ishido, Shun, Yamada, Michiko, Keitoku, Taisei, Nobusawa, Tsubasa, Higuchi, Mayu, Takaura, Kenta, Tanaka, Shohei, Maeyashiki, Chiaki, Tamaki, Nobuharu, Takahashi, Yuka, Kurosaki, Masayuki, Asahina, Yasuhiro, Okamoto, Ryuichi, Izumi, Namiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322937/ https://www.ncbi.nlm.nih.gov/pubmed/35884610 http://dx.doi.org/10.3390/cancers14143551

Ejemplares similares

Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma
por: Ishido, Shun, et al.
Publicado: (2023)

Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease
por: Ishido, Shun, et al.
Publicado: (2023)

Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
por: Ishido, Shun, et al.
Publicado: (2023)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
por: Ishido, Shun, et al.
Publicado: (2023)

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma
por: Kaneko, Shun, et al.
Publicado: (2022)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
por: Sekiguchi, Shuhei, et al.
Publicado: (2022)

Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment
por: Kaneko, Shun, et al.
Publicado: (2022)

Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population
por: Kirino, Sakura, et al.
Publicado: (2023)

Simple algorithm to narrow down the candidates to receive echocardiography in patients with chronic liver disease for suspected pulmonary hypertension
por: Yamashita, Koji, et al.
Publicado: (2022)

Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma
por: Kirino, Sakura, et al.
Publicado: (2020)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
por: Takada, Hitomi, et al.
Publicado: (2019)

Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
por: Inada, Kento, et al.
Publicado: (2021)

The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy
por: Takaura, Kenta, et al.
Publicado: (2022)

Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
por: Tamaki, Nobuharu, et al.
Publicado: (2019)

Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup
por: Tamaki, Nobuharu, et al.
Publicado: (2020)

Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib
por: Kaneko, Shun, et al.
Publicado: (2020)

Impaired brain function improved by l-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy
por: Nakanishi, Hiroyuki, et al.
Publicado: (2020)

Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens
por: Tamaki, Nobuharu, et al.
Publicado: (2015)

Pretreatment Gastric Lavage Reduces Postoperative Bleeding after Endoscopic Submucosal Dissection for Gastric Neoplasms
por: Nakanishi, Hiroyuki, et al.
Publicado: (2016)

Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma
por: Takada, Hitomi, et al.
Publicado: (2018)

Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma
por: Yasui, Yutaka, et al.
Publicado: (2016)

Correction: Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma
por: Yasui, Yutaka, et al.
Publicado: (2016)

Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio
por: Komiyama, Yasuyuki, et al.
Publicado: (2017)

Irregular vascular pattern by contrast‐enhanced ultrasonography and high serum Lens culinaris agglutinin‐reactive fraction of alpha‐fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early‐stage hepatocellular carcinoma
por: Takada, Hitomi, et al.
Publicado: (2016)

Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures
por: Takada, Hitomi, et al.
Publicado: (2019)

Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients
por: Hayashi, Tsuguru, et al.
Publicado: (2020)

Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease
por: Tamaki, Nobuharu, et al.
Publicado: (2019)

Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-Fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor
por: Osawa, Leona, et al.
Publicado: (2020)

Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy
por: Itakura, Jun, et al.
Publicado: (2015)

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases
por: Tamaki, Nobuharu, et al.
Publicado: (2021)

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
por: Saito, Naoto, et al.
Publicado: (2022)

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
por: Tsuchiya, Kaoru, et al.
Publicado: (2014)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
por: Tomonari, Tetsu, et al.
Publicado: (2022)

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
por: Iwamoto, Hideki, et al.
Publicado: (2021)

Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors
por: Izumi, Namiki, et al.
Publicado: (2010)

Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma
por: Mitsuyama, Yasuhito, et al.
Publicado: (2023)

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma
por: Tokunaga, Takayuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5240vuk183chi0i352um985fac